The money will be used to expand production capacity at Catalent’s facilities in Research Triangle Park, North Carolina and is indicative of the growth in the pulmonary and nasal drug delivery market.
A Catalent spokesperson told In-Pharmatechnologist.com that while “pMDI’s will remain a core delivery platform drugs that treat lung diseases such as asthma and COPD (Chronic Obstructive Pulmonary Disease), there is significant development efforts being made into dry powder inhalers and nasal drug delivery devices too.”
He explained that the CMO already offers a broad range of development services across inhaled dose forms, including pMDIs, dry powder inhalers (DPIs), nasal sprays and inhalation solutions.
He added that “the investment is to meet the demand from branded and generic manufacturers and isn’t linked directly to any one customer or programme.”